11:42 AM EST, 01/08/2025 (MT Newswires) -- Palvella Therapeutics ( PVLA ) said Wednesday that first patients have been dosed in the phase 2 clinical trial of Qtorin 3.9% rapamycin anhydrous gel to treat cutaneous venous malformations.

Venous malformation is the underdevelopment of veins in the body that can lead to abnormal blood vessels.

The company said the study is expected to enroll about 15 patients at least six years old across the US to evaluate the safety and efficacy of Qtorin administered topically once daily.

According to Palvella, the US Food and Drug Administration granted fast track designation to the drug in April 2024.

Price: 14.45, Change: -0.28, Percent Change: -1.90